Metabolic dysfunction-associated steatotic liver disease is reported to increase the risk of cardiovascular disease in young adults. Research is being conducted to understand the mechanisms and clinical implications of this association, including its potential link to heart failure. Various studies are exploring different aspects of the disease, such as its assessment, management, and treatment, including the use of certain medications like GLP-1 receptor agonists.